These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 6966305)

  • 1. Topical therapeutic efficacy of 9-(2-hydroxyethoxymethyl)guanine and 5-iodo-5'-amino-2',5'-dideoxyuridine on oral infection with herpes simplex virus in mice.
    Park NH; Pavan-Langston D; Hettinger ME; McLean SL; Albert DM; Lin TS; Prusoff WH
    J Infect Dis; 1980 May; 141(5):575-9. PubMed ID: 6966305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acylovir in oral and ganglionic herpes simplex virus infections.
    Park NH; Pavan-Langston D; McLean SL
    J Infect Dis; 1979 Nov; 140(5):802-6. PubMed ID: 316819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of oral HSV-1 infection model in mice. Evaluation of efficacy of 5'-amino-5-iodo-2',5'-dideoxyuridine.
    Park NH; Pavan-Langston D; Hettinger ME; Geary PA; August ML; Albert DM; Lin TS; Prusoff WH
    Oral Surg Oral Med Oral Pathol; 1982 Mar; 53(3):256-62. PubMed ID: 6278378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapeutic efficacy of E-5-(2-bromovinyl)-2'deoxyuridine for orofacial infection with herpes simplex virus type 1 in mice.
    Park NH; Pavan-Langston D; Boisjoly HM; De Clercq E
    J Infect Dis; 1982 Jun; 145(6):909-13. PubMed ID: 6979592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease and latency characteristics of clinical herpes virus isolated after acyclovir therapy.
    Sibrack CD; McLaren C; Barry DW
    Am J Med; 1982 Jul; 73(1A):372-5. PubMed ID: 6285725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of therapeutic activity of idoxuridine and acyclovir in experimentally-induced herpetic keratitis in rabbits (author's transl)].
    Colin C; Chastel C; Quillien MC; Renard G
    J Fr Ophtalmol; 1981; 4(1):33-43. PubMed ID: 7217623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, 5'-amino-5-iodo-2',5'-dideoxyuridine and 2-deoxy-D-glucose on latent ganglionic herpes simplex virus infection.
    Pavan-Langston D; Park NH; De Clercq E
    Antiviral Res; 1984 Apr; 4(1-2):53-61. PubMed ID: 6331305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy for herpes simplex virus infections.
    Erlich KS; Mills J
    West J Med; 1985 Nov; 143(5):648-55. PubMed ID: 3909643
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical characteristics of acyclovir-resistant herpetic keratitis and experimental studies of isolates.
    Yao YF; Inoue Y; Kase T; Uchihori Y; Mori Y; Ohashi Y
    Graefes Arch Clin Exp Ophthalmol; 1996 Aug; 234 Suppl 1():S126-32. PubMed ID: 8871163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent reactivable latent herpes simplex virus infection in trigeminal ganglia of mice treated with antiviral drugs.
    Svennerholm B; Vahlne A; Lycke E
    Arch Virol; 1981; 69(1):43-8. PubMed ID: 6271097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antiviral and non-antiviral general treatments for oro-facial and genital herpes (pregnancy and neonates excluded)].
    Guillaume JC
    Ann Dermatol Venereol; 2002 Apr; 129(4 Pt 2):625-34. PubMed ID: 12122333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the antiherpetic activity of acyclovir in rabbits.
    Trousdale MD; Nesburn AB
    Am J Med; 1982 Jul; 73(1A):155-60. PubMed ID: 6285707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management.
    Arduino PG; Porter SR
    Oral Dis; 2006 May; 12(3):254-70. PubMed ID: 16700734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acyclovir topical therapy of cutaneous herpes simplex virus infection in guinea pigs.
    Park NH; Pavan-Langston D; McLean SL; Lass JH
    Arch Dermatol; 1980 Jun; 116(6):672-5. PubMed ID: 7377804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycol.
    Spruance SL; Schnipper LE; Overall JC; Kern ER; Wester B; Modlin J; Wenerstrom G; Burton C; Arndt KA; Chiu GL; Crumpacker CS
    J Infect Dis; 1982 Jul; 146(1):85-90. PubMed ID: 7045255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herpes simplex infection--Part II: Management of HSV infections.
    Yarom N; Buchner A; Dayan D
    Refuat Hapeh Vehashinayim (1993); 2006 Apr; 23(2):6-13, 65. PubMed ID: 16886871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical 5 percent acyclovir in polyethylene glycol for herpes simplex labialis. Antiviral effect without clinical benefit.
    Spruance SL; Crumpacker CS
    Am J Med; 1982 Jul; 73(1A):315-9. PubMed ID: 6285721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acyclovir therapy for the orofacial and ganglionic HSV infection in hairless mice.
    Park NH; Pavan-Langston D; Hettinger ME
    J Dent Res; 1980 Dec; 59(12):2080-6. PubMed ID: 6941998
    [No Abstract]   [Full Text] [Related]  

  • 19. Pathogenesis of experimental skin infections induced by drug-resistant herpes simplex virus mutants.
    Klein RJ; Friedman-Kien AE; DeStefano E
    Infect Immun; 1981 Dec; 34(3):693-701. PubMed ID: 6277789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The natural history of recurrent oral-facial herpes simplex virus infection.
    Spruance SL
    Semin Dermatol; 1992 Sep; 11(3):200-6. PubMed ID: 1390034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.